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Diclofenac (DCF) is a prevalent anti-inflammatory drug used throughout the world. Intensive researches carried
out in the past few decades have confirmed the global ubiquity of DCF in various environmental compartments.
Its frequent occurrence in freshwater environments and its potential toxicity towards several organisms such as
fish and mussels makes DCF an emerging environmental contaminant. At typical detected environmental con-
centrations, the drug does not exhibit toxic effects towards living organisms, albeit chronic exposure may lead
to severe effects. For DCF, about 30–70% removal has been obtained through the conventional treatment system
in wastewater treatment plant being the major primary sink. Thus, the untreated DCF will pass to surface water.
DCF can interact with other inorganic contaminants in the environment particularly in wastewater treatment
plant, such asmetals, organic contaminants and evenwith DCFmetabolites. This processmay lead to the creation
of another possible emerging contaminant. In the present context, environmental fate of DCF in different com-
partments such as soil and water has been addressed with an overview of current treatment methods. In addi-
tion, the toxicity concerns regarding DCF in aquatic as well as terrestrial environment along with an
introduction to the metabolites of DCF through consumption as well as abiotic degradation routes are also
discussed. Further studies are required to better assess the fate and toxicological effects ofDCF and itsmetabolites
and must consider the possible interaction of DCF with other contaminants to develop an effective treatment
method for DCF and its traces.
© 2016 Elsevier Ltd. All rights reserved.
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1. Introduction
Pharmaceutical industry has emerged as one of the largest and
prominent industryworldwide. Large amount of pharmaceuticals of dif-
ferent categories are being used to cure and care human and animal
health. In general, pharmaceuticals comprise compoundswhich include
materials extensively used in medicine, agriculture and biotechnology,
such as drugs, antibiotics and hormones. The worldwide average per
capita consumption of pharmaceuticals per year is estimated to be
about 15 g. In industrialized countries, the usage is even as high as 50
to 150 g (Alder et al., 2006). Pharmaceutically active compounds
(PhACs) are one of the conspicuous classes of pharmaceuticals which
by one route or another, enter the environment as theparent compound
or as pharmacologically active metabolites (Halling-Sørensen et al.,
1998). It is estimated thatworldwide consumption of active compounds
amounts to 100,000 tons ormore per annum (Kummerer, 2004). Usual-
ly, drugs are developed with an intention of having a beneficial biolog-
ical effect on the organism to which they are administered, though
many such compounds will often pass into the environment where
they may exert an unwanted biological effect (Halling-Sørensen et al.,
1998). The global occurrences of pharmaceuticals and PhACs in aquatic
environment have been arising as a problem with unknown conse-
quences. PhACs have been reported to be present in different environ-
mental compartments and often the short-term as well as long-term
effects are obscure (Kunkel and Radke, 2012; Langford et al., 2011)
Hence, it has been relatively recently that PhACs have become a subject
of interest to environmentalists worldwide (Hao et al., 2007).
Among PhACs, non-steroidal anti-inflammatory drugs (NSAIDs) are
widely used throughout the world and detected in different environ-
mental compartments at concentrations ranging from ng L−1 to low
mg L−1 (Halling-Sørensen et al., 1998; Khetan and Collins, 2007).More-
over, NSAIDs are over-the-counter (OTC) drugs in most of the countries
and this in turn increases the chances for consumption and hence, their
presence in the environment. DCF is often recognized as the ‘world's
most popular pain killer’ and is also the most commonly used NSAID,
with a market share close to that of the next three most popular drugs
combined (ibuprofen, mefenamic acid, naproxen) (McGettigan and
Henry, 2013). The name diclofenac is derived from its chemical name:
2-(2,6-dichloranilino)phenylacetic acid. Diclofenac was discovered by
Ciba-Geigy, a Swiss pharmaceutical company in 1973 (now merged to
Novartis). Diclofenac is commonly used to reduce inflammation and to
relieve pain in diseased conditions, such as arthritis or acute injury. It
also works as antiuricosurics and analgesic. DCF can be applied to skin
or it can be administered orally. DCF is supplied as or contained in
medications under a variety of trade names. In Canada, DCF is sold as
Voltaren Emulgel and some other common names are Votalin (China),
Diclofenaco Normon (Spain), Volini (India), Diclofenac-Asteria (USA
and Korea), Diclo-Denk (Germany) Voltaren (Argentina, Australia, Bel-
gium, Egypt, France, Germany, Israel, New Zealand, Norway, Portugal,
Russia, South Africa, Sweden, Turkey) (sources - www.drugs.com/
diclofenac, www.drugbank.ca, www.scbt.com).
Pharmacological and physico-chemical properties of DCF are listed
in Table 1. Often DCF is not completely removed fromwastewater treat-
ment plants (WWTP) due to its poor degradation and higher consump-
tion rates (Fatta-Kassinos et al., 2011; Zorita et al., 2009). Hence, DCF is
frequently detected in rivers, sediments and sludges (Kunkel andRadke,
2012; Langford et al., 2011). Relatively recently, DCF has drawn much
more attention due to its frequent occurrence in drinkingwater sources
(Gros et al., 2010) and its potential harmful effects on many organisms
at significant concentration (Cleuvers, 2004; Oaks et al., 2004).
Diclofenac is normally used as salt of sodium or potassium for im-
proved solubility and absorption. Until date, no literature is exclusively
available on the environmental perspectives and concerns regarding the
drug, DCF. Most of the previously published reviews have discussed the
fate of diclofenac in WWTPs (Vieno and Sillanpää, 2014; Zhang et al.,
2008). The objective of this review is to briefly summarize the current
status of diclofenac in the environment, review the available informa-
tion about its consumption, occurrence, toxicity, resistance, persistence
andmetabolites. In addition this review addresses the hypothetical pos-
sibility of potential interactions of DCFwith other organic and inorganic
contaminants, emerging contaminants along with its own metabolites.
Major research gap in the current knowledge and future research
need in diclofenac fate and transport in environment have also been
highlighted.
2. Global consumption
It is fairly impossible to calculate the exact global consumption of
diclofenac because of various reasons, such as use of different trade
names for DCF, use for human and veterinary purposes and that the
drug is an over the counter drug. Nevertheless, Zhang et al. (2008) esti-
mated that about 940 tons of diclofenac is consumed globally on an an-
nual basis from Intercontinental Marketing Services (IMS) health data
(Zhang et al., 2008). About 877 tons of diclofenac were sold in 2007 in
76 major countries which are believed to account for about 96% of the
global diclofenac pharmaceutical market (Zhang et al., 2008). In a
2012 report from “Fierce Pharma”, diclofenac was listed as the 12th
bestselling generic molecule globally. The total sales of diclofenac in
Table 1
Physico-chemical and pharmacological properties of diclofenac (in unionized form).
Properties Reference
Structure www.pubchem.ncbi.nlm.nih.gov,
www.chemspider.com
Molecular formula and molecular weight C14H11Cl2NO2, 296.16 g mol−1 www.drugbank.ca, www.pubchem.ncbi.nlm.nih.gov
CAS no. 15307-86-5
15307-79-6 (disodium salt)
www.drugbank.ca, www.pubchem.ncbi.nlm.nih.gov
Water solubility 2.37 mg L−1 (25 °C) www.drugbank.ca, www.chemspider.com
Henry's law constant 4.79 × 10−7 Pa m3 mol−1 (25 °C) www.scbt.com, www.pubchem.ncbi.nlm.nih.gov
Melting and boiling points 283–285 °C and 412 °C at 760 mm Hg (predicted)
respectively
www.drugbank.ca, www.chemspider.com
pKa 4.15 www.drugbank.ca, www.chemspider.com
Log Kow (logarithm of octanol-water partition
coefficient)
4.51 www.scbt.com, www.pubchem.ncbi.nlm.nih.gov
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2011 were estimated to be $1.61 billion dollars with a sales charge of
15.5% annually (Palmer, 2012). While considering the sales change in-
formation along with previously carried-out consumption estimation,
there is high probability that the annual consumption of DCF might
have crossed 1000 tons. Moreover, recent reports suggests that along
with conventional and developed markets, such as United States,
emerging markets such as India, China and Brazil also consume
N60 tons of DCF on annual basis (Acuña et al., 2015). In addition, the
consumption estimation of DCF does not cover the veterinary consump-
tion due to non-availability of data and hence the consumption can be
even higher while considering the veterinary usages.
Diclofenac is included in the emergency medical list (EML) of 74
countries. The exact annual consumption of diclofenac in North America
is not available, even though inNorth America, themarket shares of DCF
in the drug market are on a continuous rise. In US, DCF contributes to
about 5–6% of the total NSAID market while in Canada, 17% of NSAID
consumed is DCF (Henry, 2013). According to the current trend, con-
sumption of DCFwill keep on increasing in North America since lifestyle
diseases, such as arthritis and heart diseases are now becoming com-
mon and the also the ageing population will require medicines, such
as pain killers.
The annual consumption or prescription data for diclofenac is avail-
able for some countries. According to consumption estimation models,
in Australia, it was estimated that 4 tons of DCF was used annually
(Khan andOngerth, 2004). In Europe, the largest user of DCF is Germany
with 86 tons of usage in the year 2001 (Huschek et al., 2004). For rest of
the European countries; the consumption comprises for England
26.13 tons per year (Jones et al., 2002), Austria 6.14 tons per year
(Strenn et al., 2004) and France 16 tons per year (Ferrari et al., 2003).
The total consumption of DCF in the entire European continent was es-
timated to be 179.8 tons per year (Ferrari et al., 2003). For most of the
Asian and African countries, data on consumption of DCF is not available
due to the lack of studies on consumption and also due to the absence of
inventory of sales.With the frequent reports on toxicological effects ob-
served in these countries on vultures, it can be assumed that the con-
sumption can be colossal.
Recent studies based on IMS health data (which serves 82% of the
global population) from86 countries estimated that at present on an av-
erage 1443 ± 58 tons of DCF is consumed globally (Acuña et al., 2015).
In this study authors also indicated that 39.5% of DCF was consumed in
Asia and 28.7% Europe. However, this is only an indication on the con-
sumption DCF for human health related applications and does not in-
clude the consumption of DCF for veterinary uses. At present it is
impossible to calculate the total consumption of DCF since the data for
veterinary consumption is not available.
3. Legislation
DCF in environment has been lately acknowledged to constitute a
health risk to terrestrial organisms. DCF is extremely toxic to vultures
(even though they do not consume DCF directly) and its use on cattle
has wiped out and threatened vulture populations in India, Pakistan
and Nepal since the vultures consume cattle carcasses. India was the
first country to bring in regulations on the consumption of DCF. In
2006, the manufacture and veterinary use of DCF was banned in India
(The Drug controller General, 2006). Further in 2008, India placed addi-
tional restrictions on diclofenac for animal use, with contravention pun-
ishable with imprisonment. Further, the same year, Nepal and Pakistan
banned the drug for veterinary use followed by Bangladesh in 2010
(Venkateshwarlu, 2011).
For the veterinary use, diclofenac does not have a central marketing
approval from the European Medicines Agency (EMA) and it is autho-
rized independently in eachmember state. Further, EMA has set a Max-
imum Residue Limit for DCF in bovine and porcine species. Since 2013,
the commercial production of DCF started in Spain and Italy and is
being exported to other European Union countries. A coalition of
famous organizations including the Vulture Conservation Foundation,
The Royal Society for the Protection of Birds, Bird Life Europe and the
IUCNVulture Specialist Group are campaigning for an EU-imposed, con-
tinent-wide ban on veterinary diclofenac following the lessons from
India (BirdLife, 2013; Tavares, 2014a; Tavares, 2014b). Diclofenac has
been recently added to Environmental Quality Standards (EQS) of Eu-
rope. According to the European Community document
(COM(2011)876), the annual average value of EQS (evaluation of qual-
ity standards) for DCFwas 0.1 μg L−1. However, this document has been
amended and DCF is put on watch list until next review (Johnson et al.,
2013). In 2013, DCF has been selected for inclusion in the watch list of
“EU Water Framework Directive” in order to collect sufficient monitor-
ing data for the determination of risk reduction measures. According to
this proposed EQS document , the maximimum alloable concentrations
are 0.1 μg L−1 in freshwaters and 0.01 μg L−1 inmarinewaters. Another
European coutry, United Kingdom (UK) has placedDCF in ‘the list of pri-
ority substances’ which forced the water industries to search technolo-
gies to remove DCF from wastewater.
Regulatory measures for the use of DCF has been imposed by few
countries. Apart from very few regional/country wise regulations in
global scale scenario, strict legislation or directives does not exist to reg-
ulate the production and consumption of DCF to control environmental
presence of diclofenac. Since DCF is emerging as a contaminant of con-
cern and has been acknowledged to pose health risks towards terrestrial
organisms, such as vultures, recent efforts have focussed on survey on
contamination of diclofenac in the environment and drafting the rules
for the regulation of the drug. However, there is a need to control the
consumption of drug and thereby reduce the environmental presence.
Besides, it is important to set appropriate directives, such as setting a
maximum concentration limit in the environment.
4. Environmental fate
Even though the general purpose of the pharmaceuticals is to posi-
tively affect human or animal health in a unique manner, they often
have some adverse effects on the environment. When these pharma-
ceuticals enter the environment, they may affect the same pathways
in animals having identical or similar target organs, tissues, cells or bio-
molecules (Fent et al., 2006). Studies have demonstrated the potential
adverse effects of diclofenac in the environment (Cleuvers, 2004; Gros
et al., 2010; Kunkel and Radke, 2012; Oaks et al., 2004). Hence, it is im-
portant to understand the origin and fate of pharmaceuticals and
diclofenac in particular in the environment for designing appropriate
pollution remedial measures.
Fig. 1 demonstrates the possible entry routes of DCF to the environ-
ment. Being an anthropogenic pollutant, the source of diclofenac is the
drug industry, and it is used for both human and veterinary purposes.
Through both human and veterinary routes, DCF ends up in wastewater
treatment plants or in landfills as DCF or its metabolites. Also, there are
fewer but considerable probabilities for the drug to reach wastewater
treatment plants directly from pharmaceutical industrial residues. Like-
wise, the conventional treatment process of DCF in wastewater treat-
ment plants are ineffective (Fatta-Kassinos et al., 2011; Zorita et al.,
2009) and hence DCF can endup in the surfacewater and the possibility
for the percolation of DCF to the drinking water sources cannot be
overruled. In addition, percolation probabilities for DCF from landfills
to surface water are fairly higher. At present, none of the studies report-
edDCF causingmajor risks to aquatic life at an environmentally relevant
concentration. The potential detrimental effect of DCF in the aquatic en-
vironment has been revealed from many studies (Cleuvers, 2003; Fent
et al., 2006; Jones et al., 2002; Lee et al., 2011). The no effect concentra-
tion (NEC) of DCFwas calculated to be 100 μg L−1 for freshwater cladoc-
erans and Japanesemedaka (Lee et al., 2011). Another study on rainbow
trout and zebra fish, two typical examples for freshwater organisms no
observed effect concentration (NOEC) was observed to be 320 μg L−1
(Memmert et al., 2013).
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4.1. Removal processes
The conventional treatment system includingwastewater treatment
plants exhibited a moderate to higher degradation efficiency of DCF.
DCF is moderately persistent in the environment. In the reviewed stud-
ies, themaximumremoval obtainedwas about 93%by adsorption on ac-
tivated carbon followed by ozonation (Beltran et al., 2009). Primary
treatment was also efficient with coagulating and flocculating agents,
such as FeCl3, Al2(SO4)3 but did not remove the drug completely from
wastewater (Carballa et al., 2005). Conventional activated sludge pro-
cesses showed better efficiency when compared to the MBR. On an av-
erage, 30–70% removal can be obtained by the existing removal
methods (Vieno and Sillanpää, 2014; Zhang et al., 2008). An overview
of the treatment methods is given in Table 2. The removal efficiency
mostly depends upon the treatmentmethods. For instance, the conven-
tional activated sludge process exhibited about 75% removal (Kimura et
al., 2005; Lonappan et al., 2016), however mostly this removal was
achieved through sorption to the sludge. This happened in conventional
wastewater treatment plant where a certain percent of DCF removal oc-
curred through the accumulation of the drug in wastewater sludge
(Lonappan et al., 2016). Hence, the effective removal or degradation of
the drug is minimal in conventional wastewater treatment system. Sev-
eral other treatment options which are based on sorption process have
been suggested by various researchers recently (Sotelo et al., 2014;
Sotelo et al., 2012; Suriyanon et al., 2013). Even though various natural
and synthetic adsorbentmaterials, such as activated carbon, biochar, sil-
ica based polymer based adsorbents exhibited excellent removal effi-
ciency towards DCF, as a whole, these processes cannot be considered
as sustainable methods; as they do not completely remove DCF from
the environment. Instead, water/wastewater boundDCF is accumulated
on the adsorbent. Another most widely used method for the treatment
of DCF is based on advanced oxidation processes, such as ozonation
(Beltran et al., 2009). However these methods also do have fallouts.
These processes may create unwanted and toxic by-products.
Nevertheless, few recent developments are promising and sustainable.
Studies demonstrated the effective use of enzymes for the complete
degradation of DCF from water (Marco-Urrea et al., 2010) which will
create no harmful byproducts.
4.2. Presence in aquatic environment
The potential detrimental effect of DCF in the aquatic environment
has been revealed from many studies (Cleuvers, 2003; Fent et al.,
2006; Jones et al., 2002; Lee et al., 2011). However, all these studies
were conducted at laboratory scale. In surface water bodies, DCF has
been detected in ng L−1whereas in wastewater, the concentration has
been as high as micrograms per liter. The concentration decreased by
natural processes, such as soil retention, biodegradation and photo-
transformation and also by physico-chemical processes in wastewater
treatment plants. Table 3 presents the recent occurrence of diclofenac
in the aquatic environment in different countries over a time period of
15 years. In surface waters, DCF contamination occurred in rivers, estu-
aries and lakes (Buser et al., 1998; Kim et al., 2007;Metcalfe et al., 2003;
Öllers et al., 2001). Also, there are a few reports of detection in ground-
water and drinkingwater (Benotti et al., 2008; Rabiet et al., 2006). Most
of the detection has been from EU countries, but this does not indicate
that DCF was only present in European countries. In Asia, the available
data was insufficient to predict the environmental concentrations as
there was no systematic annual data. When compared to Europe, the
consumption of DCF in North America was lower. However, there are
a few reported cases of DCF detection in the environment (Metcalfe et
al., 2003; Sosiak and Hebben, 2005).
In reviewed data, the highest concentration detected was in rivers
and was in Pakistan as 4900 ng L−1 (Scheurell et al., 2009) and one of
the potential reason could be due to the absence of advanced WWTPs
in Asian countries. Meanwhile, recent reports from Canada showed
that WWTP effluents contain very high concentration of DCF such as
16 μg L−1 (Lonappan et al., 2016). German water bodies have also
Fig. 1. Entry routes of diclofenac to the environment.
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been heavily polluted with DCF and maximum concentration detected
was 1030 ng L−1 in river water (Heberer, 2002a). In Spain, DCF residues
were detected in river Delta (Lopez-Serna et al., 2013). DCF residues
were detected in almost all European Union countries (Hernando et
al., 2006; Loos et al., 2010). In US and Germany, DCF was even detected
in drinking water which warrants attention (Benotti et al., 2008;
Heberer, 2002b).
DCF has been detected mostly in fresh water bodies all over the
world. Water containing DCF is discharged to surface water from
WWTPs after treatment. The concentration ranges from few hundreds
of ng L−1 to thousands of ng L−1. In Asian countries, there are no strict
measures to monitor the concentration of DCF in aquatic environment.
From the few available studies in rivers, it is clear that DCF is discharged
to surfacewater without proper treatment. Therefore, in this region, the
load of DCF into the aquatic environment could be reduced by proper
treatment of wastewater. Mostly, these wastewater treatment plants
must be equipped with train of primary, secondary and tertiary treat-
ment for an effective removal.
4.3. Presence in soil
There are a few reported cases of detection in DCF in soil.
Diclofenac could potentially reach agricultural lands through the ap-
plication of municipal sewage sludge as a source of nutrients in soil
or through wastewater and it has been detected in the Canadian
province of Ontario (Al-Rajab et al., 2010). Studies on the sorption
coefficient of diclofenac proved that sorption even in sandy sediment
was relevant and therefore diclofenac was less mobile in groundwa-
ter (Scheytt et al., 2005). On the other hand, studies from Israel re-
ported that DCF showed slower mobility in organic rich agricultural
soils and higher mobility in fresh water column and which caused
its leaching to the ground water and ultimately to drinking water
after rain events (Chefetz et al., 2008; Drillia et al., 2005). Few
other studies also pointed to the same possibility (Chefetz et al.,
2008; Xu et al., 2009).
The toxicity of DCF in soil towards plants and soil organisms/micro-
organisms has been poorly understood. More investigations must be
carried out in this environmental compartment. The only information
that is available is that DCF has been readily degraded in soil and was
highly adsorbed by organic rich soil (Al-Rajab et al., 2010; Xu et al.,
2009). DCF is less toxic towards leguminous plants when compared to
other pharmaceuticals, such as sulfamethazine (Ziółkowska et al.,
2014) and DCF does not show any harmful effect towards plant growth
(Carter et al., 2014b). Also, DCF does not show any toxic effects (behav-
ior, weight change, mortality) towards soil organisms, such as earth-
worms (Carter et al., 2014a). However, recent reports on soil
application of wastewater sludge containing DCF suggested medium
risks towards soil microbes (Verlicchi and Zambello, 2015).
Table 2
Removal of diclofenac in wastewater treatment plants.
Major treatment method Process conditions and other treatment methods Removal % Comments Reference
Submerged MBR Membrane flux 0.4 m3/ml/d
HRT 9 h
MLSS conc-10,000 mg L−1
40% – Kimura et al. (2005)
Conventional activated sludge HRT 13 h
MLSS conc-1700 mg L−1
75% – Kimura et al. (2005)
Adsorption on activated carbon
followed by ozonation
– N93% Activated carbon reduced toxicity Beltran et al. (2009)
Conventional biological
wastewater treatment
– 65% Average result of study on 5 biological
wastewater treatment plants in Spain
Gomez et al. (2007)
Primary treatment (coagulation
and flotation)
Coagulation-FeCl3,Al2(SO4)3
PAX
40–70% – Carballa et al. (2005)
Flotation-12 °C–25 °C 20–40%
Conventional active sludge
(CAS) treatment
Anoxic pre-denitrification and phosphate
precipitation with ferric chloride as tertiary
treatment
65% About 15% in 65% of total removal
was through adsorption on to sludge
Larsson et al. (2013)
Conventional biological
wastewater treatment
Bio-filtration type wastewater
treatment and consists of 30 bio-filters
75% Some percent of removal was occurred
through adsorption onto sludge
Lonappan et al.
(2016)
Activated sludge process – 25% – Martín et al. (2012)
MBR SRT(d)-10–55
HRT(d)-0.5–4
b50% – Clara et al. (2005)
Conventional biological
wastewater treatment
WWTP: 1
SRT-8 days
HRT-9 h
75% Study on 2 WWTPs. Accumulation
on sludge was of minor
Samaras et al. (2013)
WWTP: 2
SRT-18 days
HRT-23 h
39%
Conventional activated sludge
with chemical phosphorous
removal
HRT (h) 15–16 22% – Bendz et al. (2005)
Conventional activated sludge with
UV treatment as tertiary
treatment
– 81.4% – Behera et al. (2011)
Conventional activated sludge
with maturation pond
WWTP: 1
SRT-10 days
HRT-6 h
Conventional activated
sludge with chlorination
WWTP: 2
SRT-6 days
HRT-6 h
≈70% in all the 3
WWTPs
Study of 3 WWTPs. Anumol et al. (2016)
Aerated lagoon with filtration
and with chlorine addition
WWTP: 2
SRT-3.1 days
HRT-74 h
Activated sludge – 45.6% Average result for 15 different
WWTPs
Pereira et al. (2015)
Abbreviations - MBR: membrane bioreactor, HRT: hydraulic retention time, SRT: sludge retention time, MLSS: mixed liquor suspended solids, WWTP: wastewater treatment plant.
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From the little available information on the fate and toxicity of DCF
in soil, DCF exhibits lower toxicity and moderate persistence. However,
in soils with large amount of organic matter, DCF gets adsorbed to the
soil and exhibited resistivity towards aerobic/anaerobic degradation
and may leach out to the groundwater causing accumulated toxic ef-
fects. Thus, future studies should focus on the fate of DCF in agricultural
lands with further monitoring of fate through groundwater aquifers.
5. Toxicity
Earlier, most of the studies on the toxic effects of DCF were focused
on its adverse effects on the aquatic animals. The toxic concerns regard-
ing DCF in freshwater environment have been studied in the laborato-
ries with the help of model organism for toxicological studies. The first
widely noted case of pharmaceutical causing major ecological damage
was the sudden collapse of vultures due to the consumption of carcasses
containing residues of DCF. After these consecutive incidents in the first
decade of 20th century, DCF has gotmuchworldwide attention. The fol-
lowing section describes the toxic concerns over DCF in aquatic environ-
ment; particularly in freshwater environment and the events of DCF
toxicity towards terrestrial animals.
5.1. Aquatic organisms
Many toxicity studies were conducted worldwide to evaluate the
toxicity of DCF in aquatic organisms. One of the widely used and highly
standardizedmethods formeasuring toxicitywas the acute immobiliza-
tion tests. Ferrari et al. (2003) conducted one of the first studies on the
toxic effects of DCF. This study was carried out on bacteria, algae,
microcrustaceans and fish, and showed relatively less toxic effects
even at environmental concentrations. On the contrary, later studies
revealed the potential impacts of diclofenac on the environment. Ac-
cording to risk assessment studies, the potential ecological risk of
diclofenac in surface waters was higher (Hernando et al., 2006).
Cleuvers (2004) conducted ecotoxicity studies using acute Daphnia
and algal tests and revealed that DCFwas potentially harmful to aquatic
organisms. In the same study, Cleuvers (2004) also reflected that under
field or environmental concentrations, the adverse effects were either
less or negligible and a mixture of pharmaceuticals can be considerably
toxic even at lower concentrations. In crustacea (Daphnia magna sp.), at
acute concentrations, such as mg L−1, DCF induced high mortality rate.
From different studies for 48 h exposure, the presence of DCF produced
higher mortality and the EC50 values were reported to be 22.4 mg L−1-
and 39.9 mg L−1 (Ferrari et al., 2003; Haap et al., 2008). Also, for
Ceriodaphnia dubia sp., mortality was observed and the EC50 was
22.7 mg L−1 (Ferrari et al., 2003). On the contrary, Lee et al. (2011) re-
ported 3 times higher values for 48 h EC50 tests for the same species.
Surprisingly, studies from Canada reported that DCF was a major risk
even at predicted environmental concentrations (10–100 ng L−1)
(Lawrence et al., 2007). These studies in river biofilm communities re-
vealed the significant impacts of DCF on community structure and func-
tion at even lower concentrations of 100 ng L−1.
DCF was known to exert deadly effects by damaging renal and gas-
trointestinal tissue in several vertebrates, such as fishes. In an exposure
assessment study, Letzel et al. (2009) found that at environmentally rel-
evant concentrations, such as nanograms per liter, DCF may cause
chronic adverse effects on fish populations. In fish, Japanese medaka
(Oryzias latipes), DCF adversely affected the growth in egg phase and re-
sulted in significant reduction of hatchability and delay in hatching (Lee
et al., 2011). In a study on zebra fish, Hallare et al. (2004) observed the
same results. Hatchingwas delayedwhen the embryoswere exposed to
2000 μg L−1. In brown trout, DCF was not completely excreted through
Table 3
Recent occurrences of diclofenac in aquatic environment.
Environmental medium Concentration (ng L−1) Country Reference
River 2–3 Finland Lindqvist et al. (2005)
River 21–90 Canada Sosiak and Hebben (2005)
River 18–50 Canada Metcalfe et al. (2003)
Estuary 195 UK Thomas and Hilton (2004)
River 6.2 Germany Weigel et al. (2002)
River 1030 Germany Heberer, (2002a)
Ground water/wells 2 Mediterranean region Rabiet et al. (2006)
Wells 380 Germany Heberer et al. (1998)
Drinking water tap 10 Germany Heberer (2002b)
River 100–200 Germany Letzel et al. (2009)
River 100–4900 Pakistan Scheurell et al. (2009)
Lake 370 Switzerland Buser et al. (1998)
River 5–40 UK Kasprzyk-Hordern et al. (2008)
River 26–72 Spain, Belgium, Germany, Slovenia Hernando et al. (2006)
River 20–91 UK Hilton and Thomas (2003)
Rivers and lakes 1.1–6.8 South Korea Kim et al. (2007)
River 0.7 France Rabiet et al. (2006)
Well 0.9 France Rabiet et al. (2006)
River 9–282 Slovenia Kosjek et al. (2005)
River 20–150 Switzerland Öllers et al. (2001)
Well 4.9–24 European Union (23 countries) Loos et al. (2010)
Aquifer 1.7 Spain Lopez-Serna et al. (2013)
Well 3.1 Spain Lopez-Serna et al. (2013)
River delta 29.5–380 Spain Lopez-Serna et al. (2013)
Drinking water 1.2 US Benotti et al. (2008)
River 15.8–35.5 Austria Ahrer et al. (2001)
River 7.8–64.8 China Dai et al. (2015)
Harbor lagoon 100 Pakistan Scheurell et al. (2009)
Well 590 (max. observed) Germany Sacher et al. (2001)
River 260 (max. observed) Spain López-Serna et al. (2012)
River 15 South Korea Yoon et al. (2010)
River 49 Spain Carmona et al. (2014)
Tap water 18 Spain Carmona et al. (2014)
River 34–145 Argentina Valdés et al. (2014)
Seawater (subtropical coastal zone) 19.4 Brazil Pereira et al. (2016)
River 230 (max. observed) China Ma et al. (2016)
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first pass metabolism, but a significant part of the DCF entered
enterohepatic circulation. The resulting prolonged availability of DCF
in the organism possibly promoted accumulation of DCF (Hoeger et
al., 2008). For the same species, a heavy damage of gill, liver and kidney
was observed at 50 μg L−1 (Hoeger et al., 2005). For rainbow trout, even
at environmentally observed concentrations, DCF interfered with the
biochemical functions and lead to tissue damage (Mehinto et al.,
2010; Schwaiger et al., 2004). DCF may accumulate in liver kidney,
gills andmuscle tissues of rainbow trout and can cause cytological alter-
ations even at 1 μg L−1 (Schwaiger et al., 2004; Triebskorn et al., 2004).
Mussels got affected by DCF at concentrations that are prevalent in
the environment. At nanograms per liter level concentrations, DCF sig-
nificantly induced lipid peroxidation (LPO) in mussels indicating tissue
damage (Schmidt et al., 2011). A relatively recent study (Gonzalez-Rey
and Bebianno, 2014) proved that at 250 ng L−1, which came very close
to the concentrations in certain German rivers, DCF induced tissue spe-
cific biomarker responses leading to the tissue damage. DCF was also
adversely affecting the metabolism and growth of the blue mussels
which are common in Baltic Sea (Ericson et al., 2010).
Except for mussels, environmentally relevant concentrations ap-
peared to be less toxic for aquatic animals.Most of the studies suggested
that continuous exposure to DCF even at very low concentrations may
lead to some adverse effects in aquatic animals. It was estimated that
the no effect concentration of DCF was 0.1 mg L−1 (Lee et al., 2011),
which is very high when compared to those observed in aquatic sys-
tems/real environmental conditions (Table 3). Moreover, DCF and its
metabolites were observed in fish bile (Kallio et al., 2010). Several
photo-transformation products can be more toxic than DCF at the con-
centration that may come close to the environmental concentrations
(Schmitt-Jansen et al., 2007). However, the toxicity of metabolites of
DCF was poorly understood in the environment. The future studies
may include the toxicity studies of photo-transformation products of
DCF and mixture toxicity studies. Also, the future studies should con-
centrate on the bioaccumulation of DCF in the foodweb and chronic ex-
posure studies at lower but environmentally relevant concentrations
since the DCF residue is continuously introduced and dynamically in-
creasing in the environment.
5.2. Terrestrial organisms
The first widely noted case of pharmaceutical causingmajor ecolog-
ical damage was the sudden collapse of vultures due to the consump-
tion of carcasses containing residues of DCF, and this threatened
several vulture species to extinction (Oaks et al., 2004; Taggart et al.,
2007b). DCF was the major cause of collapse of population of three
Gyps vulture species (Gyps bengalensis, Gyps indicus, Gyps tenuirostris)
which were severely affected, reduced by 98% in the Indian sub-conti-
nent and was included in “critically endangered” species list of IUCN
(Das et al., 2010).
In 2003, studies reported the catastrophic collapse of Indian white-
backed Gyps bengalensis and long-billed Gyps indicus vulture popula-
tions due to some unknown reason or epidemics (Ferrari et al., 2004;
Prakash et al., 2003). However, the exact reason for this sudden collapse
was discovered by Oaks et al. (2004), and it was found to be the renal
portal vasoconstriction caused by DCF. On the contrary, another study
reported the cause of death as decreased uric acid excretion (Naidoo
and Swan, 2009). Most of the investigations led to the probability of
renal failure due to the consumption of DCF (Sharma et al., 2014;
Swan et al., 2006; Taggart et al., 2007a). The major food source of vul-
tures was the livestock from cows and goats. These animals were treat-
ed with DCF and although DCF was short lived in these animals, the
prevalence in carcasses available to vultures may still be very high
(Taggart et al., 2007a) and Gyps vultures were extremely susceptible
to very lower doses of DCF (Swan et al., 2006). These events even affect-
ed the ecosystem. DCF did not only affect the population of vultures but
also the community structure of the ecosystem. Vultures are keystone
species and their decline has a range of socio-economic as well as cul-
ture and biodiversity impacts. As an example, the rabies causing dogs
and vultureswere having same food source. The decrease in the number
of vultures increased the availability of food for dogs by reducing com-
petition over food (Markandya et al., 2008). Hence, the decline in vul-
tures had a biological and social effect in the specific region of concern.
The veterinary application of DCF is also threatening the vulture spe-
cies in Africa (Naidoo et al., 2009; Virani et al., 2011). There are reported
cases of major decline in the abundance of vultures and other scaveng-
ing raptors from Kenya and the reason was suspected to be DCF (Virani
et al., 2011). Moreover, relatively recently, DCF has been reported to be
fatal for eagles whichwidens the diversity of raptors threatened by DCF
(Sharma et al., 2014).
Recent studies reported that the ban of DCF for veterinary use in
south Asian countries was an effective measure and the vulture popula-
tion is on rise now (Khadka and Mandal, 2013; Prakash et al., 2012).
Hence, legislative measures succeeded for DCF in South Asia through
its ban for veterinary use. Nevertheless, there are DCF residues already
present in the environment, especially those that pass through the soil
into groundwater which need to be investigated to avoid any future
chronic toxicity effects on organisms. However, there are other terres-
trial animals which feed on the carcasses of cattle and which need to
be studied as they are the intermediate transporters of DCF during its
veterinary use.
6. Metabolites
In animals, after consumption, DCF ismostly degraded into hydroxyl
derivatives. DCF is easily degraded to its transformation products in the
environment. The major natural process of degradation is photo-trans-
formation by sunlight. DCF is one of the best investigated pharmaceuti-
cal residues in the environment (Vieno and Sillanpää, 2014; Zhang et al.,
2008). However, studies on the occurrence and toxicity of its metabo-
lites in the environment are not well understood.
6.1. Via consumption routes
In human body, DCF derivative is found in urine and plasma. The hy-
droxylated andmethoxylated derivatives of DCF are present in their free
formswell as glucuronide-conjugated forms. In an earlier study, Stierlin
et al. identified themetabolites of DCF in human body and themainme-
tabolite was identified to be 4′-hydroxydiclofenac (2-[2,6-dichloro-4
hydroxyphenylamino] phenylethanoic acid) (30%) and othermajorme-
tabolites are 5′-hydroxydiclofenac (2-[2,6-dichlorophenylamino]-5-
hydroxyphenylethanoic acid) (10%), 3′-hydroxydiclofenac (2-[2,6-
dichloro-3-hydroxyphenylamino] phenylethanoic acid) and 4′,5-
dihydroxydiclofenac (2-[2,6-dichloro-4-hydroxyphenylamino]-5-
hydroxyphenylethanoic acid) (15%) (Boettcher et al., 1991; Stierlin et
al., 1979). Recently, some minor metabolites were also identified in
human body (Stulten et al., 2008a). Along with hydroxyl derivatives of
DCF, acyl glucuronide and hydroxyl acyl glucuronide were also found
inmouse andfish (Kallio et al., 2010; Naisbitt et al., 2007). The identified
humanmetabolites of DCF are depicted in Table 4. Thewide occurrence
of humanmetabolites of diclofenac inwater and its structural similarity
towards diclofenac is amatter of concern on toxicity grounds and needs
to be investigated further.
6.2. Via abiotic degradation route
DCFwas readily degraded in the sunlight. The half-life of DCF is esti-
mated to be 3.3 h (Schmitt-Jansen et al., 2007). DCF followed first order
kinetics during photodegradation and was detected in water cycle (Qin
and Yang, 2012). Photodegradation was identified as the main removal
process for the degradation of DCF in lakes and it was estimated that
about 90% of DCF was eliminated by this process (Buser et al., 1998).
Many phototransformation products of DCF were identified by various
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researchers (Agüera et al., 2005; Moore et al., 1990; Qin and Yang,
2012). Most significant process of DCF phototransformation was identi-
fied as the photocyclisation to the correspondingmonohalogenated car-
bazole (Eriksson et al., 2010).Most of the photochemical decomposition
products occurred as two main sub-structures: 2-chloro- and 2,6-
dichlorodiphenylamine derivatives and also 8-hydroxy- and 8-
chlorocarbazole derivatives (Agüera et al., 2005; Moore et al., 1990).
Not only diclofenac, but also itsmetabolites are globally entering the
aqueous environment. There are reports that some of the DCF metabo-
lites are even more toxic than DCF. Some of the phototransformation
products exhibited a six fold increase in toxicity in algal reproduction
tests (Schmitt-Jansen et al., 2007; Schulze et al., 2010). In view of the
toxic effects of diclofenac on several water organisms, it appeared that
themetabolites also initiated objectionable reactions in other organisms
and needed strict surveillance during drug toxicological and environ-
mental monitoring experiments (Stulten et al., 2008b). Therefore, fu-
ture studies need to investigate the potential toxicity of DCF
metabolites. However, the analysis of DCF transformation products is
often laden with challenges. For example, unavailability of metabolite
standards obstructs the exact quantification of DCF transformation
products. Another analytical challenge is the low level (often nano-
grams per liter) occurrence of the drug and its transformation products.
Hence, MS/MS instruments with high sensitivity and appropriate
methods are needed to quantify this “micro-pollutant”.
7. Interactions with other pollutants-proposed approach
For diclofenac, WWTPs being one of themajor sink; interactionwith
other contaminants is a possibility that has to be studied. A hypothetical
representation of a typical secondary treatment system in wastewater
treatment plant depicting interaction of diclofenac with other pollut-
ants is shown in Fig. 2.Municipalwastewater treatment plants are com-
plex systems that receive contaminants from a variety of sources. These
include contaminants, such as suspended solids, biodegradable organics
such as proteins, carbohydrates and fats (particularly in hospital waste-
water), nutrients, such as nitrogen, phosphorus and carbon - (from var-
ious origin), refractory organics, such as pesticides, phenols, surfactants,
heavy metals, dissolved organics, and pathogens of various category
(bacteria, viruses, protozoa, etc.). In addition, they also receive various
pharmaceuticals and personal care products (PPCPs) termed as emerg-
ing contaminants. Often emerging contaminants are detected inminute
concentrations, such as ng L−1 or μg L−1. These lower concentrations
are even undetectable without specific sensitive methods. Moreover,
for pharmaceuticals, corresponding metabolites are formed during in
vivo human/veterinarymetabolism and they could become a new cate-
gory of potential emerging contaminants.
Micro-pollutants, such as pharmaceuticals are present in ‘micro’
concentrations. However, even at this micro concentration, they can
cause adverse impacts in the environment. In addition, these contami-
nants can interact/combine/aggregate with other pollutants of the
same or different class. For example, for pharmaceuticals, including
DCF, it is proven that in a mixture of pharmaceuticals, considerable
combination effects could also occur if some or even all substances
were applied in concentrations below their NOEC (no observed effect
concentration) (Cleuvers, 2004; Cleuvers, 2008).
As described in Section 5, many studies already evaluated the toxic
concerns regarding DCF in various environmental compartments. How-
ever, very few studies have examined the mixture toxicity concerns re-
garding DCF along with other pharmaceuticals. A recent study
suggested antagonistic interactions between nutrients and emerging
contaminants including DCF in stream biofilms (Aristi et al., 2016);
however long-term real exposure experiments are required to bring
out actual mixture toxicity effects. Hence, to interpose realism into fu-
ture risk assessment studies, mixture toxicity studies must focus on:
(i) whether ecotoxicity of a pharmaceutical mixture is higher than
that of the toxicity of each individual pharmaceutical; and (ii) if acting
singly at lower concentrationswhatwill be the toxicity of the individual
drug, DCF (Backhaus, 2014). These studies will thus need efforts from
environmental exposure assessment studies for toxicity evaluation. Fur-
thermore, since the number of drugs and its varieties are on an increase
along with hundreds of existing pharmaceuticals, the need for creating
database for themixture toxicity concerns of DCF alongwith other phar-
maceuticals is vital. These interactions and mixture toxicity studies
must consider toxicokinetic and toxicodynamic interactions in test or-
ganisms along with ecological interactions for real scale studies
(Backhaus, 2014).
7.1. Proposed interactions of DCF with metals, other inorganics and
organics
Conventionally, diclofenac treatment occurs in the wastewater
treatment plant. WWTP receive wastewater from various sources,
such as industries, hospitals, households and municipal wastewater,
among others. Because of the differences in origin, the contaminants
are also diverse. Metals and heavy metals, in particular is a major class
of contaminants that are usually present (Barakat, 2011; da Silva
Oliveira et al., 2007; Karvelas et al., 2003). Various physico-chemical
conditions in a conventional wastewater treatment plant can catalyze
this process. Previous studies already proved that DCF along with cer-
tain metals possess higher anti-inflammatory activity and antioxidant
property than DCF alone (Kovala-Demertzi, 2000). Moreover, DCF has
active groups such as amino, hydroxyl, carbonyl, and carboxyl groups
in its structure. These groups can enhance the metal complexation/
binding propertieswithmost of themetals. Hence, organometallic com-
plexation of drugs via chelation is a possibility that can happen in
WWTP. DCF can act as ligand coordinated to the metal ions via the
deprotonated functional groups present on it.Moreover, DCF complexes
with Hg(II), Pb(II), and Sn(II) are already known to be antibacterial
agents (Refat et al., 2014) while Cu(II) complex of DCF can cleave DNA
(Theodorou et al., 1999). Hence, on reaction with metal complexes,
the properties of DCF can change completely and become another po-
tential pollutant possessing antibacterial and cell destruction capacity.
Until date, most of the metal complexation studies of DCF commonly
have been used to uncover its novel therapeutic values and underlying
mechanisms. However, to the best of our knowledge, none of the stud-
ies focused on DCF metal complexes and its toxicity concerns in waste-
water effluent. Hence, while considering DCF as an emerging
Table 4
Human metabolites of diclofenac.
Metabolite Molecular
structure
Reference
4′-Hydroxydiclofenac Boettcher et al. (1991), Stierlin et al.
(1979), Stulten et al. (2008a))
5′-Hydroxydiclofenac Boettcher et al. (1991), Stierlin et al.
(1979), Stulten et al. (2008a)
3′-Hydroxydiclofenac Boettcher et al. (1991),
Stierlin et al. (1979)
4′,5-Dihydroxydiclofenac Boettcher et al. (1991),
Stierlin et al. (1979)
3′-Hydroxy-4′-methoxy
diclofenac
Boettcher et al. (1991)
4′-Hydroxy diclofenac
dehydrate
Stulten et al. (2008a)
1-O-acyl glucuronide
(DCF-gluc)
Willis et al. (1979)
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contaminant having potential toxic concerns towards several organ-
isms, the metal complexes of DCF must be considered as an emerging
contaminant and must be treated with care while considering its anti-
bacterial properties. The metal complexes of DCF add another chemical
complexity raising toxicity concerns for several organisms.
Moreover, because of the structural properties, DCF can act as a li-
gand for other inorganic elements/groups. This property of DCF, partic-
ularly in WWTP is crucial from toxicological point of view.
Unfortunately, none of the published studies investigated these aspects
on DCF toxicity. Theoretically, the interactionswith other inorganic pol-
lutants, such as sulfates, nitrates chlorides are a certain possibility for
DCF along with possible complexation/aggregation with other numer-
ous organic pollutants in wastewater matrix.
7.2. Proposed interactions of DCF with other ECs and DCF metabolites
Although mixture toxicity concerns with other pharmaceuticals are
already established and studied, the toxicity concerns over DCF metab-
olites are still valid. The major metabolites of DCF are hydroxy-metabo-
lites (3′-hydroxydiclofenac, 4′-hydroxydiclofenac, 5′-
hydroxydiclofenac). The mixture toxicity effects of these metabolites
are still unknown. There is a possibility for the mixture toxic effect of
DCF and these metabolites similar to one reported with other pharma-
ceuticals. In addition, various conditions existing inWWTP can catalyze
the effective combinationof thesemetabolites andDCF, and itmay leads
to the creation of another potential contaminant. In addition, about 65%
percent of DCF is present as DCFmetabolites (Boettcher et al., 1991) and
this increases the availability for all metabolites and DCF.
The reported metabolites of DCF have –OH groups at various posi-
tions in the DCF structure. Hence, the basic molecular structure of DCF
largely remains unaltered. The presence of hydroxyl groups on the
structure can enhance the interactionswithmetals throughπ-π interac-
tions. Yamada et al. (1990) applied this principle to DCF metabolites
which can easily form metal complexes since the DCF metabolites are
the hydroxyl derivatives of DCF. Moreover, due to the presence of active
groups, such as amino, hydroxyl, carbonyl, and carboxyl groups in me-
tabolites of DCF, there is a possibility of interaction between these
molecules. Hence, these possibilities point towards creation of “new
emerging contaminant” of unknown properties. Likewise, for DCF, it is
possible to have interactions with other ECs. Several other ECs, such as
pesticides, surfactants, PPCPs are present in wastewater (Petrović et
al., 2003). Often these ECs are compounds having several active groups
in their structure. Thus, it is possible to have multiple interactions with
one or many other ECs and DCF along with its metabolites. These inter-
actions could be with other ECs and/or its metabolites/transformation
products during treatment process. Recently, the synergistic effect of
DCF and its nitrogen transformation products were studied along with
sulfamethoxazole and its transformation products (Osorio et al., 2016)
suggesting that contribution of these compounds to overall toxicity of
complex environmental samples, should not be dismissed.
Hence, experimental evidence is necessary for these interactions to
perform toxicity studies and drafting adequate risk assessment for
DCF. However, the existing ecotoxicological and environmental expo-
sure data is not sufficient and realistic while considering WWTP as the
major sink for DCF. Future studies, particularly toxicity focus on these
mixtures of ECs, metabolites, metals and DCF that are either proven or
likely to form new products. To further increase the realism of ecotoxi-
cological studies, investigation based on these approaches is necessary
with overwhelming number of emerging contaminants being added
each day.
8. Conclusions
Diclofenac is one of the major PhACs which has a far flung usage
throughout the world. The residues of diclofenac are found worldwide
in surface, ground and drinking water. Even though diclofenac is re-
moved by natural processes, such as photodegradation, the residue
still remains in the environment as potential toxic metabolites and as
diclofenac. Diclofenac in the environment is detected in lower concen-
trations, such as nanograms per liter to micro grams per liter and from
the available ecotoxicology data, it is apparent that these lower concen-
trations can cause acute toxic effects to many organisms, such as mus-
sels. At lower measured concentrations, there are fewer chances of
acute toxicity. However, extended exposure to lower concentrations
Fig. 2. Hypothetical representation of a typical secondary treatment system in wastewater treatment plant showing interaction of diclofenac with other pollutants.
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may lead to chronic toxicological effects In the case of diclofenac, con-
tinuous entry into the environment due to the year-round use of medi-
cation is increasing the diclofenac residue in the environment. The fate
of diclofenac in soil is poorly understood. In soils, with large amount of
organic matter, diclofenac gets adsorbed to the soil and shows resistiv-
ity towards aerobic/anaerobic degradation and may leach out to the
groundwater causing toxic effects. The toxicity of diclofenacmetabolites
is not well investigated and some studies suspected that few metabo-
lites can be potentially more toxic than the parent compound. There
still remains a lacuna for investigating the environmental impact of me-
tabolites and also the toxicological effects if any, on the flora and fauna.
Diclofenac can interact with other inorganic contaminants, such as
metals, organic contaminants and even with diclofenac metabolites as
they all are present in a complex wastewater matrix in wastewater
treatment plant. This process may lead to the formation of another pos-
sible emerging contaminant. Further studies are required to better as-
sess the fate and toxicological effects of diclofenac and its metabolites
andmust consider the possible interaction of diclofenacwith other con-
taminants to develop an effective treatment method for diclofenac and
transformation products. Moreover along with DCF, DCF metabolites
must be considered as another emerging contaminant and treatment
methods must emphasize metabolites as well. The tertiary treatment
system must be equipped with more advanced treatment methods,
such as advanced oxidation and environmental friendly enzymatic
treatmentmethodswhich are known to be effective for several contam-
inants including DCF.
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